Quality of Life and Economic Impacts of Retinitis Pigmentosa on Japanese Patients: A Non-interventional Cross-sectional Study
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Retinitis pigmentosa (RP) is an inherited progressive disease, characterized by a loss of photoreceptors, and is the second leading cause of visual impairment in Japan. RP is currently incurable and can result in complete blindness, with affected patients typically experiencing a gradual loss of light sensitivity, visual field, and visual acuity. Identification of any unmet medical needs of patients with this condition requires an understanding of the impacts of RP; in this study, we surveyed Japanese patients with RP to investigate the quality of life and economic impacts of visual impairment. METHODS: This non-interventional, cross-sectional study surveyed Japanese patients with RP. Economic impact was measured using an original questionnaire that assessed out-of-pocket cost (e.g., vision aids and medical services), salary gap with the general public, and the cost of depression and anxiety. Worker productivity was assessed using the Work Productivity and Activity Impairment Questionnaire (WPAI). Quality of life was evaluated using the Health Utilities Index Mark 3 (HUI3), the National Eye Institute Visual Function Questionnaire-25 (VFQ-25), and the 5-level EQ-5D version (EQ-5D-5L). The primary outcome was direct and indirect costs of visual impairment or blindness during the lifetime of patients with RP. RESULTS: Among 122 surveyed patients with RP, the estimated annual cost per patient was 218,520 yen (2176 USD), and the estimated lifetime cost per patient was 18,523,909 yen (184,501 USD). Additional robustness testing increased the estimated annual cost and lifetime cost per patient to 783,176 yen (7801 USD) and 66,389,827 yen (661,253 USD), respectively. In working patients, work productivity loss was 26.2% per person and impairment of daily activities was 31.6% per person. The mean VFQ-25, HUI3, and EQ-5D-5L scores were 42.0, 0.393, and 0.833, respectively. CONCLUSION: RP imposed a heavy economic burden and negative quality of life impacts in Japanese patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“other international studies suggested that 81% to 90% of the costs associated with IRDs are indirect and intangible [80–84].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [83]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guides to the Evaluation of Permanent Impairment
(1971) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1971.03190110063016 · Cited by 796
Prevalence and Causes of Low Vision and Blindness in a Japanese Adult Population
Iwase, A., Araie, M., Tomidokoro, A., Yamamoto, T., Shimizu, H., & Kitazawa, Y. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.04.022 · Cited by 544 · cited 1×
“RP is a progressive disease, whereby affected patients experience a gradual loss of light sensitivity, visual field, and visual acuity, and can lead to complete blindness [2, 3].”
Wittenborn, J. S., Zhang, X., Feagan, C. W., Crouse, W. L., Shrestha, S., Kemper, A. R., Hoerger, T. J., & Saaddine, J. B. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.01.068 · Cited by 186 · cited 1×
“…loss has been reported to be higher than indirect costs: one study estimated annual costs of 98.7 billion USD and indirect costs of 35.5 billion USD [34], and an earlier study of a population younger than 40 years estimated direct costs of 14.5 billion USD and indirect costs of 13 billion USD [35].”
InfluentialThe Impact of Age-Related Macular Degeneration on Health Status Utility Values
Espallargues, M., Czoski-Murray, C. J., Bansback, N. J., Carlton, J., Lewis, G. M., Hughes, L. A., Brand, C. S., & Brazier, J. E. (2005) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.05-0072 · Cited by 150 · cited 1×
“However, the EQ-5D-5L index score did not correlate with any visual impairment measures, which is consistent with previous reports [11, 29–31].”
Morizane, Y., Morimoto, N., Fujiwara, A., Kawasaki, R., Yamashita, H., Ogura, Y., & Shiraga, F. (2018) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-018-0623-4 · Cited by 138
The Economic Burden of Vision Loss and Blindness in the United States
Rein, D. B., Wittenborn, J. S., Zhang, P., Sublett, F., Lamuda, P. A., Lundeen, E. A., & Saaddine, J. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2021.09.010 · Cited by 128 · cited 1×
“…loss has been reported to be higher than indirect costs: one study estimated annual costs of 98.7 billion USD and indirect costs of 35.5 billion USD [34], and an earlier study of a population younger than 40 years estimated direct costs of 14.5 billion USD and indirect costs of 13 billion USD [35].”
InfluentialGalvin, O., Chi, G., Brady, L., Hippert, C., Del Valle Rubido, M., Daly, A., & Michaelides, M. (2020) · Clinical Ophthalmology · doi:10.2147/opth.s241928 · Cited by 116 · cited 1×
“…been reported in other countries, including the Republic of Ireland and the UK [40,680 USD/person (27,988 pounds ster-ling/person) and 36,541 USD/person (25,140 pounds sterling/person), respectively; 0.688 pounds sterling was converted to 1 USD to calculate the USD equivalent of each cost] [33].”
InfluentialRetinitis pigmentosa: recent advances and future directions in diagnosis and management
Fahim, A. T. (2018) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000690 · Cited by 105 · cited 3×
“Retinitis pigmentosa (RP) is one of the inherited retinal dystrophies, which are a heterogeneous group of eye disorders that can result in visual impairment and eventual blindness [1].”
Cost of anxiety disorders in Japan in 2008: a prevalence-based approach
Sado, M., Takechi, S., Inagaki, A., Fujisawa, D., Koreki, A., Mimura, M., & Yoshimura, K. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-338 · Cited by 92
Seeing through their eyes: lived experiences of people with retinitis pigmentosa
Senthil, M. P., Khadka, J., & Pesudovs, K. (2017) · Eye · doi:10.1038/eye.2016.315 · Cited by 80 · cited 1×
“This is consistent with prior studies [38–40], and highlights the need for new treatments and support to improve the lives of affected patients.”
Cited by
Cost-of-illness studies of inherited retinal diseases: a systematic review
Ng, Q. X., Ong, C., Yaow, C. Y. L., Chan, H. W., Thumboo, J., Wang, Y., & Koh, G. C. H. (2024) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-024-03099-9 · Cited by 27
“Four studies were from the United States (US) [7, 19– 21] (one with Canada [7]), and one each from Australia [22], Denmark [23], Japan [24], Singapore [25], and the United Kingdom (UK) with Republic of Ireland (RoI) [6].”
BackgroundResultInfluentialManaging Retinitis Pigmentosa: A Literature Review of Current Non-Surgical Approaches
Colombo, L., Baldesi, J., Martella, S., Quisisana, C., Antico, A., Mapelli, L., Montagner, S., Primon, A., & Rossetti, L. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020330 · Cited by 19
Patient-Reported Social Impact of Molecularly Confirmed Retinitis Pigmentosa
Zehe-Lindau, N., Lindau, B., Stöhr, H., Weber, B. H. F., Spital, G., & Kellner, U. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093229 · Cited by 7
“Childhood-onset IRD has been shown to reduce lifetime income by approximately one-third [9–11] and raise personal healthcare expenses [12,13].”
Yin, G. S., Shao, Z., Faghfoury, H., & Ballios, B. G. (2024) · Ophthalmology Retina · doi:10.1016/j.oret.2024.08.007 · Cited by 5
Qu, S., Zhu, Y., Pfeiffer, N., & Grus, F. H. (2024) · Nutrients · doi:10.3390/nu16213747 · Cited by 5
“The patient develops the disease in childhood, with early symptoms of night blindness, followed by a gradual loss of peripheral vision fields and eventually complete blindness [7].”
Background
Metadata
- Authors
- Watanabe, K., Aouadj, C., Hiratsuka, Y., Yamamoto, S., & Murakami, A.
- Affiliations
- Novartis (Japan) (JP)
- Juntendo University (JP)
- Japan Community Healthcare Organization (JP)
- Corresponding author
- Watanabe, Katsuhiko
- Venue
- Advances in Therapy
- Published
- 2023-03-22
- Volume
- 40
- Issue
- 5
- Pages
- 2375-2393
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- PMC
- PMC10032244
- OpenAlex
- W4353021311
- Cited by
- 13
- References
- 26
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 4 · 2023: 1
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Advances in Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Novartis Pharma K.K.
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- retinitis pigmentosa, quality of life, economic burden, visual impairment, blindness, lifetime costs, out-of-pocket costs, work productivity loss, activity impairment, Japanese patients
- MeSH terms
- East Asian People, Blindness, Cross-Sectional Studies, Humans, Quality of Life, Surveys and Questionnaires, Retinitis Pigmentosa
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quality of Life and Economic Impacts of Retinitis Pigmentosa on Japanese Patients: A Non-interventional Cross-sectional Study. https://app.cochat.ai/papers/10.1007/s12325-023-02446-9
- The paper
- Watanabe, K., Aouadj, C., Hiratsuka, Y., Yamamoto, S., & Murakami, A. (2023). Quality of Life and Economic Impacts of Retinitis Pigmentosa on Japanese Patients: A Non-interventional Cross-sectional Study. Advances in Therapy. https://doi.org/10.1007/s12325-023-02446-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.